Copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2004
We read with great interest the article by Teunissen et al1 in which the evolution of Charcot-Marie-Tooth disease type 2 (CMT2) was thoroughly quantified by examining a cohort of 43 patients during a 5-year period. Some points deserve further comment and elucidation. As indicated by the authors, CMT2 is genetically heterogeneous, but genetic characterization is only partially possible; therefore, it is likely that the conclusions of this study will have to be reconsidered in light of new information about the CMT2 gene, possibly defining different modes of the disease course for different genotypes. It would be interesting to know if specific clinical features were associated with slower or faster deterioration, as a possible clue to suspect different genotypes.
Gemignani F, Marbini A. Disease Course of Charcot-Marie-Tooth Disease Type 2 and Comorbidity. Arch Neurol. 2004;61(9):1470. doi:10.1001/archneur.61.9.1470-a